Q2 EPS Estimate for Akebia Therapeutics Decreased by Analyst

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share estimates for Akebia Therapeutics in a research note issued on Friday, February 6th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will post earnings per share of $0.02 for the quarter, down from their previous forecast of $0.04. HC Wainwright has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Akebia Therapeutics’ Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.05 EPS, FY2026 earnings at $0.12 EPS, FY2029 earnings at $0.30 EPS and FY2030 earnings at $0.44 EPS.

Several other analysts also recently issued reports on AKBA. Piper Sandler decreased their price objective on shares of Akebia Therapeutics from $6.00 to $4.00 and set an “overweight” rating for the company in a report on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Akebia Therapeutics in a research report on Wednesday, January 21st. Wall Street Zen downgraded Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Finally, BTIG Research reiterated a “buy” rating and issued a $5.00 price objective on shares of Akebia Therapeutics in a research note on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $5.60.

Akebia Therapeutics Stock Up 7.9%

Shares of Akebia Therapeutics stock opened at $1.50 on Monday. Akebia Therapeutics has a 12-month low of $1.30 and a 12-month high of $4.08. The company has a quick ratio of 1.80, a current ratio of 1.94 and a debt-to-equity ratio of 1.15. The stock has a 50 day moving average price of $1.51 and a two-hundred day moving average price of $2.31. The stock has a market capitalization of $398.06 million, a P/E ratio of -21.43 and a beta of 0.38.

Hedge Funds Weigh In On Akebia Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Baird Financial Group Inc. raised its holdings in Akebia Therapeutics by 23.0% in the 1st quarter. Baird Financial Group Inc. now owns 21,393 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 4,000 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Akebia Therapeutics by 9.4% in the second quarter. ProShare Advisors LLC now owns 51,266 shares of the biopharmaceutical company’s stock valued at $187,000 after purchasing an additional 4,388 shares in the last quarter. Legal & General Group Plc lifted its position in Akebia Therapeutics by 26.0% in the second quarter. Legal & General Group Plc now owns 23,279 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,798 shares during the period. PDS Planning Inc lifted its position in Akebia Therapeutics by 11.1% in the second quarter. PDS Planning Inc now owns 50,000 shares of the biopharmaceutical company’s stock worth $182,000 after purchasing an additional 5,000 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its stake in Akebia Therapeutics by 25.2% during the second quarter. Ameritas Investment Partners Inc. now owns 25,525 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 5,145 shares in the last quarter. 33.92% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CAO Richard C. Malabre sold 49,524 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.39, for a total transaction of $68,838.36. Following the completion of the transaction, the chief accounting officer owned 299,390 shares of the company’s stock, valued at approximately $416,152.10. This represents a 14.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.00% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders.

Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach.